MoA—A person rarely gets infected by just one virus particle. They come in millions attached to tiny droplets. We do not know yet how the dose of the novel coronavirus that infects a person affects the intensity of the disease. But we do know from other viruses that the dose matters. People who catch a higher dose of viruses will usually have a more intense disease. A mask can lower the virus load the wearer may receive. One can improvise a mask from simple household objects.
MEDICINE & SCIENCE
CAPITALIST SICKNESSHEALTH & MEDICINEMEDICINE & SCIENCE
In search of a coronavirus killer: Can existing drugs really turn the tide in the Covid-19 pandemic?
RT.COM—A drug called remdesivir, originally developed to treat the Ebola virus, has been another widely discussed treatment option. Designated an ‘orphan drug’ (one which treats extremely rare conditions and is therefore commercially underdeveloped) by the FDA, remsedivir emerged as one of the “most promising” treatments in numerous Western media reports. In the US, the Pentagon even rushed to secure doses of the experimental drug for US troops who have contracted the virus.
ALICE McCARTHY—According to the World Health Organization, older people and people with preexisting medical conditions appear to be more vulnerable to becoming severely ill with COVID-19.
“Elderly individuals have a different immune system than healthy middle-aged adults and often do not respond as robustly to immunization, so a one-size vaccine does not fit all,” said Ofer Levy, professor of pediatrics at Harvard Medical School and director of the PVP.
The U.S. Food and Drug Administration (FDA) took significant steps to increase the availability of ventilators and other respiratory devices, to support patients with respiratory failure or difficulty breathing. “Hospitals and other healthcare providers can repurpose (breathing) machines they have to serve as ventilators.” With a predicted shortfall of hospital ventilators needed to treat people diagnosed with COVID-19 disease with breathing problems, the FDA has authorized the use of Continuous Positive Airway Pressure (CPAP) and similar devices to help cover the forecasted shortage.
When China’s health leadership announced they have found the anti-influenza drug Avigan (Favipiravir) effective in treating COVID-19 disease in adult patients, Japan was expected to follow. China’s positive reception of Avigan (Favipiravir) contrasts with Japan’s continued reservations. Avigan initially obtained regulatory approval in Japan during 2014. Since then, clinical studies have indicated Avigan (Favipiravir) may cause serious side effects. However, on March 17, 2020, Zhang Xinmin, China’s director of the National Center for Biotechnology Development said ‘Avigan (Favipiravir) was found to be effective in clinical trials during 2020.’ These studies in China concluded this medicine was effective in treating coronavirus-related symptoms and had no obvious side effects.